Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enzalutamide - Astellas Pharma/Medivation

Drug Profile

Enzalutamide - Astellas Pharma/Medivation

Alternative Names: ASP-9785; MDV-3100; Xtandi

Latest Information Update: 14 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at Los Angeles; University of Texas M. D. Anderson Cancer Center
  • Developer Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; H. Lee Moffitt Cancer Center and Research Institute; M. D. Anderson Cancer Center; Medivation; National Cancer Institute (USA); Queen Mary University of London; The Prostate Cancer Clinical Trials Consortium; University of California, Davis; University of Chicago; University of Rochester
  • Class Antineoplastics; Benzamides; Fluorobenzenes; Imidazolidines; Nitriles; Small molecules; Thiones
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Bladder cancer; Endometrial cancer; Ovarian cancer; Salivary gland cancer
  • Phase I Pancreatic cancer
  • Discontinued Breast cancer; Liver cancer

Most Recent Events

  • 11 Feb 2019 Efficacy and adverse events data from the phase III ARCHES trial for Prostate cancer prior released by Pfizer and Astellas Pharma
  • 31 Jan 2019 Astellas Pharma announces intention to submit regulatory applications for Prostate cancer in 2021 (Astellas Pharma pipeline, February 2019)
  • 31 Jan 2019 Astellas Pharma announces intention to submit regulatory applications to the US FDA, the EMA and the MHLW for Prostate cancer by mid-2019 (Astellas Pharma pipeline, February 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top